Friday 6 November 2026 Export TGTX’s income statement to Excel — free account

TG Therapeutics, Inc.

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue: +70.3%
EPS: −73.7%
Free cash flow: +427.1%
Total debt: +204.2%

Quarter to June 2026, against a year earlier

Revenue growth 3 yrs

59.08 1.10 +1.90%

Follow TGTX

Alert me

Market cap: $8.9B
P/E: 19.1×
Fwd P/E: 62.4×
Dividend yield: —
F-score: 5/9
Altman Z: 6.29
Beneish M: 0.80
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

TG Therapeutics, Inc. (TGTX) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, TG Therapeutics, Inc. (TGTX) trades at a P/E ratio of 19.1×. Over the past ten years it has ranged from 0.0× (December 2024) to 266× (January 2024); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 10.3× and below the Healthcare sector median of 25.2×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TGTX/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="TG Therapeutics, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TGTX/metrics/pe-ratio">TG Therapeutics, Inc. (TGTX) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	9.7×	(94.52%)
FY2024	177×	(16.87%)
FY2023	213×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Jun 2026	18.1×	73.00%
Mar 2026	10.4×	7.58%
Dec 2025	9.7×	(17.49%)
Sep 2025	11.8×	(86.59%)
42 more quarters	Free account

Against its own ten years

Low 0.0× High 266×

Ten-year median 0.0×

Current reading's percentile 87

Company	P/E ratio
TWST Twist Bioscience Corporation compare	n/m
SYRE Spyre Therapeutics, Inc. compare	n/m
CYTK Cytokinetics, Incorporated compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
MDGL Madrigal Pharmaceuticals, Inc. compare	n/m
TGTX TG Therapeutics, Inc.	19.1×
KRYS Krystal Biotech, Inc. compare	39.2×
CAI Caris Life Sciences,�Inc. compare	77.7×
PTGX Protagonist Therapeutics, Inc. compare	111×
Biotechnology industry median	10.3×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

TG Therapeutics, Inc. (TGTX) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on TGTX

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on TGTX

Stockrow Weekly